Author:
Sader Helio S.,Rhomberg Paul R.,Farrell David J.,Jones Ronald N.
Abstract
ABSTRACTCXA-101, a novel oxyimino-aminothiazolyl cephalosporin, CXA-201 (CXA-101 combined with tazobactam), and various comparators were susceptibility tested by broth microdilution methods against 1,301 well-characterized clinical strains collected worldwide, including ceftazidime-resistant members of the familyEnterobacteriaceaeandKlebsiella pneumoniaecarbapenemase (KPC)- and extended-spectrum β-lactamase (ESBL)-producing strains ofPseudomonas aeruginosaandBacteroides fragilis. CXA-201 was 2- to 32-fold more active than ceftazidime and piperacillin-tazobactam against ceftazidime-resistantEnterobacteriaceaespecies but less active than cefepime for some species. CXA-101 and CXA-201 were very active againstP. aeruginosa(MIC50, 1 μg/ml for both compounds), including imipenem-resistant strains.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference11 articles.
1. In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance;Bulik;Antimicrob. Agents Chemother,2010
2. Antimicrobial susceptibility patterns of KPC-producing or CTX-M-producing Enterobacteriaceae;Castanheira;Microb. Drug Resist,2010
3. M11-A7. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard: seventh edition;Clinical and Laboratory Standards Institute.,2007
4. M07-A8. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard: eighth edition;Clinical and Laboratory Standards Institute.,2009
5. M100-S21. Performance standards for antimicrobial susceptibility testing: 21st informational supplement;Clinical and Laboratory Standards Institute.,2011
Cited by
108 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献